ArticleFrontiers in pharmacology2020
Ethanol Extract of
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer.Acta pharmacologica Sinica · 2026Review
- Potential of Traditional Chinese MedicineNutrients · 2025Review
- Programmed cell death in triple-negative breast cancer.Cellular & molecular biology letters · 2025Review
- Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer.World journal of clinical oncology · 2025Review
- Plant-derived extracellular vesicles as a novel tumor-targeting delivery system for cancer treatment.Frontiers in cell and developmental biology · 2025Review
- Chloroquine inhibits salinomycin-induced autophagy for collaborative anticancer effect in breast cancer.BioImpacts : BI · 2025Article
- Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Data on LC-MS profile ofData in brief · 2024Article
- Hotspots and future trends of autophagy in Traditional Chinese Medicine: A Bibliometric analysis.Heliyon · 2023Review
- A review ofFrontiers in pharmacology · 2023Review
- Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology.Frontiers in endocrinology · 2023Article
- Dichotomous role of autophagy in cancer.Asian biomedicine : research, reviews and news · 2022Review
- M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.Molecular cancer · 2022Article
- Huaier Induces Immunogenic Cell DeathFrontiers in cell and developmental biology · 2022Article
- Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cellsFrontiers in pharmacology · 2022Article
- TRPS1 knockdown inhibits angiogenic vascular mimicry in human triple negative breast cancer cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Article
- Renal Cellular Autophagy in Obesity: Boon or Bane?Seminars in nephrology · 2021Review
- The polyphenol/saponin-rich Rhus tripartita extract has an apoptotic effect on THP-1 cells through the PI3K/AKT/mTOR signaling pathway.BMC complementary medicine and therapies · 2021Article
- Anti-inflammatory effects of brucea javanica oil via inhibition of NF-κB activation.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive disease with worst prognosis than other subtypes of breast cancer. Owing to the lack of hormone receptors and HER2 expression on TNBC cells, patients do not have targeted therapy options available with other breast cancer subtypes. Extensive efforts have been made to identify novel therapeutics against TNBC. Interestingly, recent studies had shown that plant-derived natural products could modulate the autophagy and induce the breast cancer cells death. Seed of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.